Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression
We performed a retrospective analysis on 124 patients with transfusion-dependent thalassemia who were registered in the German pediatric registry for stem cell transplantation. All patients underwent first allogeneic hematopoietic stem cell transplantation (HSCT) between 2011 and 2020 and belonged m...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
07 February 2024
|
| In: |
Bone marrow transplantation
Year: 2024, Jahrgang: 59, Heft: 5, Pages: 587-596 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-024-02219-0 |
| Online-Zugang: | Resolving-System, kostenfrei: https://doi.org/10.1038/s41409-024-02219-0 Resolving-System, kostenfrei: https://doi.org/10.25673/116937 
|
| Verfasserangaben: | Barbara Meissner, Peter Lang, Peter Bader, Manfred Hoenig, Ingo Müller, Roland Meisel, Johann Greil, Martin G. Sauer, Markus Metzler, Selim Corbacioglu, Birgit Burkhardt, Matthias Wölfl, Brigitte Strahm, Kinan Kafa, Oliver Basu, Holger N. Lode, Bernd Gruhn, Holger Cario, Ann-Kathrin Ozga, Martin Zimmermann, Andrea Jarisch and Rita Beier |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1885324820 | ||
| 003 | DE-627 | ||
| 005 | 20241205140748.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-024-02219-0 |2 doi | |
| 024 | 7 | |a 10.25673/116937 |2 doi | |
| 035 | |a (DE-627)1885324820 | ||
| 035 | |a (DE-599)KXP1885324820 | ||
| 035 | |a (OCoLC)1475287469 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Meissner, Barbara |e VerfasserIn |0 (DE-588)144017792 |0 (DE-627)704676621 |0 (DE-576)340358629 |4 aut | |
| 245 | 1 | 0 | |a Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression |c Barbara Meissner, Peter Lang, Peter Bader, Manfred Hoenig, Ingo Müller, Roland Meisel, Johann Greil, Martin G. Sauer, Markus Metzler, Selim Corbacioglu, Birgit Burkhardt, Matthias Wölfl, Brigitte Strahm, Kinan Kafa, Oliver Basu, Holger N. Lode, Bernd Gruhn, Holger Cario, Ann-Kathrin Ozga, Martin Zimmermann, Andrea Jarisch and Rita Beier |
| 264 | 1 | |c 07 February 2024 | |
| 300 | |b Diagramme | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.06.2024 | ||
| 520 | |a We performed a retrospective analysis on 124 patients with transfusion-dependent thalassemia who were registered in the German pediatric registry for stem cell transplantation. All patients underwent first allogeneic hematopoietic stem cell transplantation (HSCT) between 2011 and 2020 and belonged mainly to Pesaro risk class 1–2. Four-year overall (OS) and thalassemia-free survival (TFS) were 94.5% ± 2.9% and 88.0% ± 3.4% after treosulfan-fludarabine-thiotepa- and 96.9% ± 3.1% (P = 0.763) and 96.9% ± 3.1% (P = 0.155) after busulfan-fludarabine-based conditioning. Mixed chimerism below 75% occurred predominantly in treosulfan-based regimens (27.5% versus 6.2%). OS and TFS did not differ significantly between matched sibling, other matched family and matched unrelated donor (UD) HSCTs (OS: 100.0%, 100.0%, 96.3% ± 3.6%; TFS: 96.5% ± 2.4%, 90.0% ± 9.5%, 88.9% ± 6.0%). However, mismatched UD-HSCTs performed less favorable (OS: 84.7% ± 7.3% (P = 0.029); TFS: 79.9% ± 7.4% (P = 0.082)). We generated a scoring system reflecting the risk to develop mixed chimerism in our cohort. The main risk-reducing factors were a high CD3+ cell count (≥6 × 107/kg) in the graft, busulfan-conditioning, pre-conditioning therapy and low-targeted ciclosporin A trough levels. Acute GvHD grade III-IV in treosulfan-based concepts predominantly occurred in patients with UD and reduced GvHD prophylaxis but not in the context of high CD3+ cell doses. Taken together, this information might be used to develop more risk-adapted HSCT regimens for thalassemia patients. | ||
| 540 | |q DE-3 |a Namensnennung 4.0 International |f CC BY 4.0 |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 650 | 4 | |a Anaemia | |
| 650 | 4 | |a Stem-cell therapies | |
| 700 | 1 | |a Greil, Johann |e VerfasserIn |0 (DE-588)1078331979 |0 (DE-627)838332455 |0 (DE-576)450711498 |4 aut | |
| 700 | 1 | |a Kafa, Kinan |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 59(2024), 5, Seite 587-596 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g number:5 |g pages:587-596 |g extent:10 |a Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41409-024-02219-0 |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.25673/116937 |x Resolving-System |z kostenfrei |
| 951 | |a AR | ||
| 992 | |a 20240628 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1078331979 |a Greil, Johann |m 1078331979:Greil, Johann |d 910000 |d 910500 |d 50000 |e 910000PG1078331979 |e 910500PG1078331979 |e 50000PG1078331979 |k 0/910000/ |k 1/910000/910500/ |k 0/50000/ |p 7 | ||
| 999 | |a KXP-PPN1885324820 |e 4543039696 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"pubHistory":["Nachgewiesen 19.1997 -"],"part":{"volume":"59","text":"59(2024), 5, Seite 587-596","extent":"10","year":"2024","issue":"5","pages":"587-596"},"note":["Gesehen am 17.01.25"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppressionBone marrow transplantation","recId":"320433366","language":["eng"],"title":[{"title_sort":"Bone marrow transplantation","title":"Bone marrow transplantation"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"London ; Basingstoke ; London","dateIssuedDisp":"1997-","dateIssuedKey":"1997","publisher":"Springer Nature ; Macmillan ; Nature Publishing Group"}],"id":{"zdb":["2004030-1"],"eki":["320433366"],"issn":["1476-5365"]}}],"physDesc":[{"noteIll":"Diagramme","extent":"10 S."}],"name":{"displayForm":["Barbara Meissner, Peter Lang, Peter Bader, Manfred Hoenig, Ingo Müller, Roland Meisel, Johann Greil, Martin G. Sauer, Markus Metzler, Selim Corbacioglu, Birgit Burkhardt, Matthias Wölfl, Brigitte Strahm, Kinan Kafa, Oliver Basu, Holger N. Lode, Bernd Gruhn, Holger Cario, Ann-Kathrin Ozga, Martin Zimmermann, Andrea Jarisch and Rita Beier"]},"id":{"doi":["10.1038/s41409-024-02219-0","10.25673/116937"],"eki":["1885324820"]},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"07 February 2024"}],"language":["eng"],"recId":"1885324820","type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 28.06.2024"],"person":[{"given":"Barbara","family":"Meissner","role":"aut","roleDisplay":"VerfasserIn","display":"Meissner, Barbara"},{"given":"Johann","family":"Greil","role":"aut","roleDisplay":"VerfasserIn","display":"Greil, Johann"},{"given":"Kinan","family":"Kafa","role":"aut","display":"Kafa, Kinan","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression","title":"Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression"}]} | ||
| SRT | |a MEISSNERBAFINDINGABA0720 | ||